Literature DB >> 16304320

Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia?

Diane E Stover1, Debra Mangino.   

Abstract

Some macrolides have been found to exert anti-inflammatory effects. Lung diseases such as asthma, panbronchiolitis, cystic fibrosis, and bronchiectasis are thought to respond to the immunomodulatory properties of macrolides. We report three cases of idiopathic bronchiolitis obliterans organizing pneumonia, now called cryptogenic organizing pneumonia, and three cases of radiation-related bronchiolitis obliterans organizing pneumonia that responded to macrolide therapy. An explanation of why macrolides may have anti-inflammatory effects in patients with these syndromes is discussed. These cases help to reinforce accumulating data that macrolides are beneficial as anti-inflammatory agents and organizing pneumonia may be another pulmonary disease that can benefit from such therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304320     DOI: 10.1378/chest.128.5.3611

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  Antibiotic use in the management of pulmonary nodules.

Authors:  Saira Khokhar; Svetlana Mironov; Venkatraman E Seshan; Diane E Stover; Rohit Khirbat; Marc B Feinstein
Journal:  Chest       Date:  2009-09-25       Impact factor: 9.410

2.  Organizing Pneumonia After Exposure to Sodium Hypochlorite: A Case Report.

Authors:  Inês Santos; Sandra Lucas; Rui Seixas; Ireneia Lino
Journal:  Cureus       Date:  2020-12-11

3.  Seven patients with cryptogenic organizing pneumonia succesfully treated with clarithromycin.

Authors:  Fatma Ciftci; Özlem Özdemir Kumbasar
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

4.  Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients.

Authors:  A L Vieira; A Vale; N Melo; P Caetano Mota; J M Jesus; R Cunha; S Guimarães; C Souto Moura; A Morais
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

5.  A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia.

Authors:  Nicolas Petitpierre; Vincent Cottin; Sylvain Marchand-Adam; Sandrine Hirschi; Dominique Rigaud; Isabelle Court-Fortune; Stéphane Jouneau; Dominique Israël-Biet; Anita Molard; Jean-François Cordier; Romain Lazor
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 6.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

Review 7.  Mycoplasma pneumoniae and its role in asthma.

Authors:  Nazima Nisar; Randeep Guleria; Sanjay Kumar; Tirlok Chand Chawla; Nihar Ranjan Biswas
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

8.  Acute respiratory failure caused by organizing pneumonia secondary to antineoplastic therapy for non-Hodgkin's lymphoma.

Authors:  Adriell Ramalho Santana; Fábio Ferreira Amorim; Paulo Henrique Alves Soares; Edmilson Bastos de Moura; Marcelo de Oliveira Maia
Journal:  Rev Bras Ter Intensiva       Date:  2012-12

9.  Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review.

Authors:  Qun-Li Ding; Dan Lv; Bi-Jiong Wang; Qiao-Li Zhang; Yi-Ming Yu; Shi-Fang Sun; Zhong-Bo Chen; Hong-Ying Ma; Zai-Chun Deng
Journal:  Exp Ther Med       Date:  2015-01-15       Impact factor: 2.447

10.  Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.

Authors:  Atsuya Takeda; Yuichiro Tsurugai; Naoko Sanuki; Tatsuji Enomoto; Masaharu Shinkai; Tomikazu Mizuno; Yousuke Aoki; Yohei Oku; Takeshi Akiba; Yu Hara; Etsuo Kunieda
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.